Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ)
CNY 25.59
(0.35%)
CNY 25.59
(0.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 602.28 Million | 688.62 Million | 614.68 Million | 524.12 Million | 620.16 Million | 590.87 Million |
| Cost of Revenue | 369.72 Million | 354.88 Million | 264.79 Million | 214.08 Million | 120.25 Million | 44.21 Million |
| Gross Profit | 232.55 Million | 333.74 Million | 349.89 Million | 310.04 Million | 499.9 Million | 546.66 Million |
| Operating Expenses | 375.63 Million | 338.42 Million | 341.46 Million | 326.24 Million | 445.39 Million | 429.98 Million |
| Selling, General and Administrative Expenses | 165.1 Million | 158.69 Million | 187.62 Million | 192.8 Million | 337.34 Million | 383.06 Million |
| Research and Development Expenses | 128.9 Million | 121.43 Million | 103.16 Million | 86.12 Million | 62.64 Million | 29.85 Million |
| Other Expenses | 81.62 Million | -1 Million | -883.86 Thousand | -14.02 Million | -10.76 Million | -192.17 Thousand |
| Cost and Expenses | 745.35 Million | 693.31 Million | 606.25 Million | 540.32 Million | 565.64 Million | 474.19 Million |
| Operating Income | -143.07 Million | -6.82 Million | 21.33 Million | -35.07 Million | 75.05 Million | 105.24 Million |
| Interest Expense | 2.39 Million | 1.11 Million | 496.72 Thousand | 463.64 Thousand | 4650.47 | 158.51 Thousand |
| Income Tax Expense | -23.74 Million | 74.18 Thousand | -9.55 Million | -11.69 Million | 11.42 Million | 13.58 Million |
| Earnings before Tax | -151.98 Million | -7.82 Million | 20.45 Million | -37.36 Million | 72.61 Million | 105.05 Million |
| Net Income | -120.82 Million | -14.02 Million | 27.65 Million | -25.02 Million | 63.03 Million | 94.13 Million |
| Earnings Per Share Basic | -0.93 | -0.11 | 0.26 | -0.24 | 0.61 | 0.91 |
| Earnings Per Share Diluted | -0.93 | -0.11 | 0.26 | -0.24 | 0.61 | 0.91 |
| Weighted Average Shares Outstanding | 129.91 Million | 122.1 Million | 106.36 Million | 103.35 Million | 103.35 Million | 103.35 Million |
| Weighted Average Shares Outstanding (Diluted) | 129.91 Million | 122.1 Million | 106.36 Million | 103.35 Million | 103.35 Million | 103.44 Million |
| Gross Margin | 0.39 | 0.48 | 0.57 | 0.59 | 0.81 | 0.93 |
| EBIT Margin | -0.12 | 0.10 | 0.12 | 0.07 | 0.18 | 0.28 |
| Profit Margin | -0.20 | -0.02 | 0.04 | -0.05 | 0.10 | 0.16 |
| EBITDA | -73.65 Million | 46.76 Million | 60.07 Million | -6.39 Million | 97.47 Million | 118.95 Million |
| Earnings Before Tax Margin | -0.24 | -0.01 | 0.03 | -0.07 | 0.12 | 0.18 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 166.36 Million | 150.78 Million | 131.88 Million | 163.85 Million | 602.28 Million | 151.97 Million |
| Cost of Revenue | 92.62 Million | 86.41 Million | 79.25 Million | 100.32 Million | 345.05 Million | 80.04 Million |
| Gross Profit | 73.73 Million | 64.36 Million | 52.63 Million | 63.52 Million | 257.22 Million | 71.93 Million |
| Operating Expenses | 96.97 Million | 87.6 Million | 105.03 Million | 104.74 Million | 363.56 Million | 95.29 Million |
| Selling, General and Administrative Expenses | 122.7 Million | 39.74 Million | 77.22 Million | -7.29 Million | - | 90.3 Million |
| Research and Development Expenses | 30.05 Million | 28.74 Million | 27.93 Million | 38.16 Million | - | 39.6 Million |
| Other Expenses | -55.78 Million | -19.11 Million | -555.5 Thousand | -2.81 Million | -8.91 Million | -4.16 Million |
| Cost and Expenses | 189.6 Million | 174.02 Million | 184.28 Million | 205.06 Million | 708.62 Million | 175.34 Million |
| Operating Income | -20.51 Million | -23.24 Million | -27.89 Million | -99.99 Million | -143.07 Million | -20.28 Million |
| Interest Expense | 637.99 Thousand | 223.17 Thousand | 1.18 Million | 673.52 Thousand | 2.39 Million | 627.79 Thousand |
| Income Tax Expense | -4.31 Million | 5.92 Million | -10.95 Million | -4.18 Million | -23.74 Million | -7.65 Million |
| Earnings before Tax | -22.06 Million | -1.02 Million | -28.44 Million | -102.81 Million | -151.98 Million | -24.45 Million |
| Net Income | -16.97 Million | -6.22 Million | -16.54 Million | -94.38 Million | -120.82 Million | -15.31 Million |
| Earnings Per Share Basic | -0.13 | -0.05 | -0.13 | -0.72 | - | -0.12 |
| Earnings Per Share Diluted | -0.13 | -0.05 | -0.13 | -0.72 | - | -0.12 |
| Weighted Average Shares Outstanding | 130.89 Million | 130.89 Million | 127.27 Million | 130.89 Million | 129.91 Million | 130.89 Million |
| Weighted Average Shares Outstanding (Diluted) | 130.89 Million | 130.89 Million | 127.27 Million | 130.89 Million | 129.91 Million | 130.89 Million |
| Gross Margin | 0.44 | 0.43 | 0.40 | 0.39 | 0.43 | 0.47 |
| EBIT Margin | -0.13 | -0.00 | -0.39 | -0.18 | - | -0.17 |
| Profit Margin | -0.10 | -0.04 | -0.13 | -0.58 | -0.20 | -0.10 |
| EBITDA | -21.43 Million | -38.59 Thousand | -51.28 Million | -29.26 Million | - | -25.08 Million |
| Earnings Before Tax Margin | -0.12 | -0.15 | -0.21 | -0.61 | -0.24 | -0.13 |
QIIWI
STAR-B
002390
LRDSF
PODP
SNRG